Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines

Prostate

Volumn 42, Issue 1, 2000, Pages 1-7

  Chung, Theodore D K ^a,b   Yu, Jianqing J ^a   Kong, Tony A ^b   Spiotto, Michael T ^a   Lin, James M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Apoptosis; Interleukin 6; Phosphatidylinositol 3 kinase; Prostate cancer; Wortmannin

Indexed keywords

CELL DNA; ENZYME ANTIBODY; GLYCOPROTEIN GP 130; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DNA DETERMINATION; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN PROTEIN INTERACTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; APOPTOSIS; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; INTERLEUKIN-6; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033988528     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000101)42:1<1::AID-PROS1>3.0.CO;2-Y     Document Type: Article

References (51)

1. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-3753.
2. Knabbe C, Kellner U, Schmahl M, Voigt KD. Growth factors in human prostate cancer cells: implications for an improved treatment of prostate cancer. J Steroid Biochem Mol Biol 1991;40:185-192.
3. Siegall CB, Nordan RP, FitzGerald DJ, Pastan II. Cell-specific cytotoxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL6-PE40) on tumor cells. Mol Cell Biol 1990;19:2443-2447.
4. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997;57:141-146.
5. Chung TDK, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1997;38:199-207.
6. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993;120:1281-1288.
7. Miki S, Iwano M, Miki Y, Yamamoto M, Tang T, Yokokawa K, Sonoda T, Hirano T, Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989;250:607-610.
8. Miles SA, Rezai AR, Salazar-Gonzalez JF, Meyden MV, Stevens RH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T, Martinez-Maza O. AIDS-Kaposi's sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 1990;40:4068-4072.
9. Yee C, Biondi A, Wang HH, Iscove NN, de Sousa J, Aarde LA, Wong GG, Clark SD, Messner HA, Minden MD. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 1989;74:798-804.
10. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-526.
11. Chiu JJ, Sgagias MK, Cowan KH. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res 1996;2:215-221.
12. Hirano T, Kishimoto T. Interleukins: molecular biology and immunology. In: Kishimoto T, editor. Chemical immunology. Basel: Karger; 1992. p 153-180.
13. Lord KA, Abdollahi A, Thomas SM, DeMarco M, Brugge JS, Hoffman-Liebermann B, Liebermann DA. Mol Cell Biol 1991;11: 4371-4379.
14. Nakajima K, Wall R. Interleukin-6 signals activating junB and TIS11 gene transcription in a B-cell hybridoma. Mol Cell Biol 1991;11:1409-1418.
15. Yuan JP, Wegenka UM, Lutticken C, Buschmann J, Decker T, Schindler C, Heinrich PC, Horn F. The signalling pathways of interleukin-6 and gamma interferon converge by the activation of different transcription factors which bind to common responsive DNA elements. Mol Cell Biol 1994;14:1657-1668.
16. Lutticken C, Wegenka UM, Yuan J, Ruschmann J, Schindler C, Zimiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T, Kishimoto T, Barbieri G, Pellegrini S, Sendtner M, Heinrich PC, Horn F. Transcription factor APRF and JAK1 kinase associate with the interleukin-6 receptor signal transducer, gp130, and are tyrosine phosphorylated in response to interleukin-6. Science 1994;263: 89-92.
17. Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn BA, Quelle FW, Silvennoinen O, Barbieri G, Pellegrini S, Ihle JN, Yancopoulos GD. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 receptor components. Science 1994;263: 92-95.
18. Wegenka UM, Buschmann J, Lutticken C, Heinrich PC, Horn F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 1993;13:276-288.
19. Stahl N, Farruggella TJ, Boulton TG, Zhong Z, Darnell JE Jr, Yancopoulos G. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995;267:1349-1353.
20. Spiotto MT, Chung TDK. STAT3 mediates IL-6 induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate. In press.
21. Takahashi-Tezuka M, Hibi M, Fujitani Y, Fukada T, Yamaguchi T, Hirano T. Tec tyrosine kinase links the cytokine receptors to PI-3 kinase probably through JAK. Oncogene 1997;14:2273-2282.
22. Dhand R, Hiles I, Panayotou G, Roche S, Fry MJ, Gout I, Totty N, Truong O, Vicendo P, Yonezawa K, Kasuga M, Courtneidge SA, Waterfield M. PI3 kinase is a dual specificity enzyme: autoregulation by an intrinsic protein serine kinase activity. EMBO J 1994;13:522-533.
23. Carpenter CL, Auger KR, Duckworth BC, Hou W-M, Schaffhausen B, Cantley LC. A tightly associated serine/threonine protein kinase regulates phosphoinositide 3-kinase activity. Mol Cell Biol 1993;13:1657-1665.
24. Kashishian A, Kazlauskas A, Cooper JA. Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase. EMBO J 1992;11:1373-1382.
25. Okada T, Kawano Y, Sakakibara T, Hazeki O, Ui M. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. J Biol Chem 1994; 269:3568-3573.
26. Whitman M, Kaplan D, Roberts T, Cantley L. Evidence for two distinct phosphatidylinositol kinases in fibroblasts: implications for cellular regulation. Biochem J 1987;247:165-174.
27. Varticovski L, Druker B, Morrison D, Cantley L, Roberts T. The colony stimulating factor-1 receptor associates with and activates phosphatidylinositol-3 kinase. Nature 1989;342:699-702.
28. Peles E, Lamprecht R, Ben-Levy R, Tzahar E, Yarden Y. Regulated coupling of the Neu receptor to phosphatidylinositol 3′-kinase and it release by oncogenic activation. J Biol Chem 1992; 267:12266-12274.
29. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell 1994;76:253-262.
30. Degeorges A, Tatoud R, Fauvel-Lafeve F, Podgorniak M-P, Millot G, De Cremoux P, Calvo F. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LN-CaP prostate cancer cells, identified as interleukin-6. Int J Cancer 1996;68:207-214.
31. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, Kitaoka T, Fukada T, Hibi M, Hirano T. A central role for STAT3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996;15:3651-3658.
32. Shimozaki K, Nakajima K, Hirano T, Nagata S. Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells. J Biol Chem 1997;272:25184-25189.
33. Yamanaka Y, Nakajima K, Fukada T, Hibi M, Hirano T. Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for STAT3 activation. EMBO J 1996;15:1557-1565.
34. Wu YY, Bradshaw RA. Induction of neurite outgrowth by interleukin-6 is accompanied by activation of STAT3 signaling pathway in a variant PC-12 cell (E2) line. J Biol Chem 1996;271: 13023-13032.
35. Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Shi W, Yang CH. STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type 1 interferon receptor. Science 1997;276:1418-1420.
36. Coughlin SR, Escobedo JA, Williams LT. Role of phosphatidylinositol kinase in PDGF receptor signal transduction. Science 243;1191-1194.
37. Valius M, Kazlauskas A. Phospholipase C-gamma 1 and phosphatidylinositol 3 kinase are downstream mediators of PDGF receptor's mitogenic signal. Cell 1993;73:321-334.
38. Kaplan DR, Whitman M, Schaffhausen B, Pallas DC, White M, Cantley L, Roberts TM. Common elements in growth factor stimulation and oncogenic transformation: 85kd phosphoprotein and phosphatidylinositol kinase activity. Cell 1987;50:1021-1029.
39. Franke TF, Yang S, Chan TO, Datta K, Kaziauskas A, Morrison DK, Kaplan DR, Tsichlis PN. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995;81:727-736.
40. Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J. PDGF-and insulin-dependent pp70S6 k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994;370:71-75.
41. Nakanishi H, Brewer KA, Exton JH. Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1993;268:13-16.
42. Eberle M, Traynor-Kaplan AE, Sklar LA, Norgauer J. Is there a relationship between phosphatidylinositol trisphosphate and F-actin polymerization in human neutrophils? J Biol Chem 1990; 265:16725-16728.
43. Hiles ID, Otsu M, Volinia S, Fry MJ, Gout I, Dhand R, Panayatou G, Ruiz-Larrea F, Thompson A, Tatty NF, Hsuan JJ, Courtneidge SA, Parker J, Waterfield MD. Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell 1992;70:419-429.
44. Hill SR, Berggren MM, Powis G. The involvement of phosphatidylinositol-3′-kinase in the synthesis of glycosylphosphatidylinositol anchors. Proc Am Assoc Cancer Res 1995;36:55.
45. Afford SC, Pongracz J, Stockley RA, Crocker J, Burnett D. The induction by human interleukin-6 of apoptosis in the promonocytic cell line U937 and human neutrophils. J Biol Chem 1992; 267:21612-21616.
46. Yonish-Rouach E, Resntzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-347.
47. Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1987;11:701-713.
48. Schultz RM, Merriman RL, Andis SL, Bonouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K, Powis G. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 1995;15:1135-1140.
49. Oikawa T, Shimamura M. Potent inhibition of angiogenesis by wortmannin, a fungal metabolite. Eur J Pharmacol 1996;318:93-96.
50. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995;55:4633-4639.
51. Nakajima Y, DelliPizzi AM, Mallouh C, Ferreri NR. TNF-mediated cytotoxicity and resistance in human prostate cancer cell lines. Prostate 1996;29:296-302.